| Literature DB >> 27806314 |
Jie Gao1, Linting Wei1, Jiali Wei2, Ganglian Yao1, Li Wang1, Meng Wang3, Xinghan Liu3, Cong Dai3, Tianbo Jin4, Zhijun Dai3, Rongguo Fu1.
Abstract
Toll-like receptors (TLRs) are a family of transmembrane receptors, and play a vital role in recognizing invading pathogens and activating innate immunity. Previous studies indicated that TLR1 single nucleotide polymorphisms (SNPs) might be associated with the risk of IgA nephropathy (IgAN). This study aims to investigate the relationship between TLR1 SNPs (rs4833095 and rs5743557) and IgAN in a Chinese Han population. This case-control study included 351 patients with IgAN and 310 healthy controls. Two SNPs (rs4833095 and rs5743557) of TLR1 were genotyped by Sequenom MassARRAY. Odds ratios (OR) with 95% confidence intervals (CI) were used to assess the relationship with IgAN. We found that both allele and genotype frequencies of rs5743557 were not associated with IgAN risk. Rs4833095 increased IgAN risk compared with controls in the allele, dominant and log-additive models (P = 0.04, 0.04 and 0.03, respectively). Further haplotype analysis revealed that the Trs4833095Trs5743557 haplotype may be a risk factor for IgAN (OR = 1.28; 95% CI = 1.01-1.63; P = 0.046). Furthermore, rs4833095 was associated with Lee's grades (OR = 1.75; 95% CI = 1.03-2.96; P = 0.04). However, there was no significant association between the genotype distributions of rs5743557 and clinical parameters of IgAN such as gender, 24 hour urine protein, blood pressure, and Lee's grades. Taken together, these findings suggest that the TLR1 rs4833095 polymorphism may play a role in the development and progression of IgAN.Entities:
Keywords: IgAN; case-control study; single nucleotide polymorphism; susceptibility; toll-like receptor 1
Mesh:
Substances:
Year: 2016 PMID: 27806314 PMCID: PMC5347750 DOI: 10.18632/oncotarget.12965
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Demographical and clinical informations of study subjects
| Characteristics | Case | Control | ||
|---|---|---|---|---|
| 351 | 310 | |||
| 32±11.9 | 35±12.6 | 0.45 | ||
| 229 | 186 | |||
| 122 | 124 | 0.16 | ||
| 159.5±146.0 | ||||
| 8.2±5.9 | ||||
| 34.0±7.9 | ||||
| 2.8±1.7 | ||||
| 1.1±0.3 | ||||
| 6.1±1.4 | ||||
| <3.5 | 272 | |||
| ≥3.5 | 79 | |||
| <140/90 | 194 | |||
| ≥140/90 | 157 | |||
| I+II+III | 260 | |||
| IV+V | 91 | |||
P values was calculated from two-sided chi-square test;
P values were calculated by Student t tests.
SCr = Serum Creatinine, BUN = Blood Urea Nitrogen, ALB= Serum Albumin, Cho = Cholesterol.
The associations between TLR1 SNPs and IgAN
| Model | Genotype | Control | Case | Before adjusted | After adjusted | AIC | BIC | ||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | ||||||||
| 132(42.6%) | 124(35.3%) | 1.00 | 0.12 | 1.00 | 0.10 | 589.7 | 612.1 | ||
| 141(45.5%) | 172 (49%) | 1.30(0.93-1.81) | 1.36(0.98-2.11) | ||||||
| 37 (11.9%) | 55 (15.7%) | 1.58(0.98-2.57) | 1.53(0.91-2.90) | ||||||
| 132(42.6%) | 124(35.3%) | 1.00 | 0.056 | 1.00 | 0.04 | 587.8 | 605.8 | ||
| 178(57.4%) | 227(64.7%) | 1.36(0.99-1.86) | 1.40(1.02-2.13) | ||||||
| 273(88.1%) | 296(84.3%) | 1.00 | 0.16 | 1.00 | 0.26 | 589.6 | 607.6 | ||
| 37 (11.9%) | 55 (15.7%) | 1.37(0.88-2.15) | 1.29(0.82-2.34) | ||||||
| 169(54.5%) | 179 (51%) | 1.00 | 0.37 | 1.00 | 0.23 | 589.4 | 607.3 | ||
| 141(45.5%) | 172 (49%) | 1.15(0.85-1.56) | 1.22(0.91-1.83) | ||||||
| --- | --- | --- | 1.27(1.01-1.59) | 0.038 | 1.25(1.04-1.65) | 0.03 | 587.9 | 605.8 | |
| 405 | 420 | 1.27(1.01-1.58) | 0.04 | --- | --- | --- | --- | ||
| 215 | 282 | --- | --- | --- | --- | ||||
| 96(31%) | 92(26.2%) | 1.00 | 0.31 | 1.00 | 0.39 | 590.4 | 612.9 | ||
| 151(48.7%) | 175(49.9%) | 1.21(0.84-1.73) | 1.18(0.73-1.89) | ||||||
| 63 (20.3%) | 84 (23.9%) | 1.39(0.90-2.15) | 1.49(0.84-2.66) | ||||||
| 96 (31%) | 92 (26.2%) | 1.00 | 0.18 | 1.00 | 0.30 | 589.3 | 607.2 | ||
| 214 (69%) | 259(73.8%) | 1.26(0.90-1.77) | 1.26(0.81-1.97) | ||||||
| 247(79.7%) | 267(76.1%) | 1.00 | 0.26 | 1.00 | 0.23 | 588.9 | 606.9 | ||
| 63 (20.3%) | 84 (23.9%) | 1.23(0.85-1.79) | 1.35(0.82-2.21) | ||||||
| 159(51.3%) | 176(50.1%) | 1.00 | 0.77 | 1.00 | 0.96 | 590.3 | 608.3 | ||
| 151(48.7%) | 175(49.9%) | 1.05(0.77-1.42) | 0.99(0.66-1.48) | ||||||
| --- | --- | --- | 1.18(0.95-1.47) | 0.13 | 1.22(0.91-1.62) | 0.18 | 588.5 | 606.5 | |
| 343 | 359 | 1.18(0.95-1.47) | 0.13 | --- | --- | --- | --- | ||
| 277 | 343 | --- | --- | --- | --- | ||||
Percentage of typed samples: 661/661 (100%); OR: odds ratio; 95% CI: 95% confidence interval; AIC: Akaike information criterion; BIC: Bayesian Information Criterion; Adjusted by age and gender.
Haplotype analysis of TLR1 and the associations with the risk of IgAN
| rs4833095 | rs5743557 | Frequency | OR (95% CI) | |
|---|---|---|---|---|
| C | C | 0.502 | 1.00 | --- |
| T | T | 0.347 | 1.28 (1.00 - 1.63) | 0.046 |
| C | T | 0.122 | 0.97 (0.68 - 1.37) | 0.86 |
| T | C | 0.029 | 1.07 (0.55 - 2.09) | 0.84 |
OR: odds ratio, 95% CI: 95% confidence interval.
Genotype association analysis of TLR1 variants with clinical parameters of IgAN
| Variables | rs4833095 | rs5743557 | ||||||
|---|---|---|---|---|---|---|---|---|
| C/C (%) | C/T-T/T (%) | OR (95%CI) | C/C (%) | C/T-T/T (%) | OR (95%CI) | |||
| 41 (33.6%) | 81 (66.4%) | 1.00 (reference) | 33 (27.1%) | 89 (72.9%) | 1.00 (reference) | |||
| 83 (36.2%) | 146 (63.8%) | 0.62 | 0.89 (0.56-1.41) | 59 (25.8%) | 170 (74.2%) | 0.79 | 1.07 (0.65-1.76) | |
| 101 (37.1%) | 171 (62.9%) | 1.00 (reference) | 76 (27.9%) | 196 (72.1%) | 1.00 (reference) | |||
| 23 (29.1%) | 56 (70.9%) | 0.19 | 1.44 (0.84-2.45) | 16 (20.2%) | 63 (79.8%) | 0.17 | 1.53 (0.83-2.81) | |
| 67 (34.5%) | 127 (65.5%) | 1.00 (reference) | 47 (24.2%) | 147 (75.8%) | 1.00 (reference) | |||
| 57 (36.3%) | 100 (63.7%) | 0.73 | 0.93 (0.60-1.44) | 45 (28.7%) | 112 (71.3%) | 0.35 | 0.80 (0.49-1.28) | |
| 100 (38.5%) | 160 (61.5%) | 1.00 (reference) | 66 (25.4%) | 194 (74.6%) | 1.00 (reference) | |||
| 24 (26.4%) | 67 (73.6%) | 0.04 | 1.75 (1.03-2.96) | 26 (28.6%) | 65 (71.4%) | 0.06 | 1.80 (0.98-3.30) | |
OR: odds ratio, 95% CI: 95% confidence interval.
P value was calculated from two-sided chi-square test.
Primers used for this study
| SNP_ID | 1st-PCRP | 2nd-PCRP | UEP_SEQ |
|---|---|---|---|
| ACGTTGGATGCCTAAG | ACGTTGGATGCTGGAG | TTCAATGTTGTTTAAGGTAAGA | |
| ACGTTGGATGGTGTGT | ACGTTGGATGACTTTAA | GACCCCTCCCTCTTT |